The Most Expensive Drugs In The World That Are Costing America Billions

From The Retirement Nerds.

šŸ’° Did you know there’s a prescription drug that costs $4.25 MILLION per dose? In this video, I break down the 3 most expensive prescription drugs in the world and reveal why the REAL pharmaceutical money-makers aren’t what you’d expect.

šŸ”¬ THE 3 MOST EXPENSIVE DRUGS:
– Lenmeldy – $4.25 Million (Metachromatic Leukodystrophy)
– Hemgenix – $3.5 Million (Hemophilia B)
– Elevidys – $3.2 Million (Duchenne Muscular Dystrophy)

šŸ’Š HIGHEST REVENUE DRUGS (Volume Strategy):
– Keytruda – $29.5 Billion/year (Cancer Treatment)
– Ozempic – $17.5 Billion/year (Diabetes/Weight Loss)
– Dupixent – $13.5 Billion/year (Inflammatory Conditions)

WORLD’S LARGEST HOSPITAL BILL VIDEO:

Check out our resources at https://TheRetirementNerds.com/

=============================
Send me a message!
Erik@TheRetirementNerds.com
=============================

šŸ”” SUBSCRIBE to The Retirement Nerds for weekly videos on retirement planning, healthcare costs, Medicare strategies, and financial education.

============================================================
Join our newsletter for monthly tips, book recommendations, and personal stories!

Newsletter


============================================================

ā° TIME CODES ā°
0:00 Intro
0:37 #3 Elevidys
1:58 #2 Hemgenix
3:29 #1 Lenmeldy
7:25 Highest Revenue Drugs
8:08 #3 Dupixent
9:04 #2 Ozempic
11:09 #1 Keytruda
12:56 Most Expensive vs Most Profitable
13:55 Retirement Healthcare Costs
14:50 What’s Most Important?

āš ļø DISCLAIMER: This video is for educational purposes only and should not be considered medical or financial advice. Always consult with qualified healthcare and financial professionals for personalized guidance.

#RetirementPlanning #PrescriptionDrugs #HealthcareCosts #Medicare #DrugPricing #Pharmaceuticals #GeneTherapy #RetirementNerds #FinancialPlanning #MedicalExpenses #ozempic

šŸ“Š DATA SOURCES: Information gathered from pharmaceutical company financial reports, FDA approvals, clinical trial data, and peer-reviewed medical literature (2024-2025).